Pharm

Janus Kinase Inhibitor

search

Janus Kinase Inhibitor, Janus Kinase, JAK Inhibitor, Ruxolitinib, Jakafi, Tofacitinib, Xeljanz, Upadacitinib, Rinvoq

  • See Also
  1. Baricitinib
  2. Biologic Agent
  • Indications
  1. Rheumatoid Arthritis
  2. Polycythemia Vera
  • Mechanism
  1. Interferes with Cytokine signalling on receptor binding
  • Preparations
  1. Ruxolitinib or Jakafi (JAK1 and JAK2 Inhibitor)
    1. Indicated in Rheumatoid Arthritis and Myelofibrosis (including Polycythemia Vera)
  2. Baricitinib or Olumiant (JAK1 and JAK2 inhibitor)
    1. Indicated in Rheumatoid Arthritis and Alopecia Areata
  3. Upadacitinib or Rinvoq (JAK1 inhibitor)
    1. Indicated in Rheumatoid Arthritis
  4. Tofacitinib or Xeljanz (JAK3 Inhibitor)
    1. Indicated in Rheumatoid Arthritis and Psoriasis
    2. Multiple black box warnings
      1. Serious infections
      2. Thrombosis (e.g. Venous Thromboembolism)
      3. Cardiovascular events (e.g. Myocardial Infarction)
      4. Lung Cancer
      5. Increased mortality
    3. References
      1. (2021) Presc Lett 28(4): 22
  • Adverse Effects
  1. Venous Thromboembolism
  2. Sudden cardiovascular death (associated with Tofacitinib)
  3. Immunosuppression
    1. Tuberculosis reactivation risk (test for Latent Tb before starting)
    2. Increased risk of opportunistic infection (e.g. invasive fungal infections, Pneumonia, Shingles)
    3. Malignancy risk (e.g. Lymphoma)
  • Precautions
  1. Avoid Live Vaccines
  • References
  1. (2019) Presc Lett 26(10): 58